Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial-Reference-Cited by-同舟云学术

Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial

Published:2023-12 Issue:12 Volume:53 Page:2346-2349
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Alexander Marliese¹²^ORCID,Collins Ian³⁴^ORCID,Abraham Patrick⁵,Underhill Craig⁶⁷^ORCID,Harris Sam⁸,Torres Javier⁹¹⁰,Sharma Sharad¹¹,Solomon Benjamin²¹²,Tran‐Duy An⁵,Burbury Kate²¹³

Affiliation:

1. Pharmacy Department Peter MacCallum Cancer Centre Melbourne Victoria Australia

2. Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne Victoria Australia

3. Victorian Comprehensive Cancer Centre Melbourne Victoria Australia

4. Deakin University Melbourne Victoria Australia

5. Centre for Health Policy, Melbourne School of Population and Global Health The University of Melbourne Melbourne Victoria Australia

6. Border Medical Oncology and Haematology Research Unit Albury Wodonga Regional Cancer Centre Albury Wodonga New South Wales Australia

7. Rural Medical School University of New South Wales Sydney New South Wales Australia

8. Bendigo Cancer Centre Bendigo Health Bendigo Victoria Australia

9. Peter Copulos Cancer and Wellness Centre Goulburn Valley Health Shepparton Victoria Australia

10. Shepparton Clinical School The University of Melbourne Shepparton Victoria Australia

11. Ballarat Regional Integrated Cancer Centre Grampians Health Ballarat Victoria Australia

12. Department of Medical Oncology Peter MacCallum Cancer Centre Melbourne Victoria Australia

13. Department of Haematology Peter MacCallum Cancer Centre Melbourne Victoria Australia

Abstract

AbstractThis cost analysis, from a societal perspective, compared the cost difference of a networked teletrial model (NTTM) with four regional hubs versus conventional trial operation at a single metropolitan specialist centre. The Australian phase 3 cancer interventional randomised controlled trial included 152 of 328 regional participants (patient enrolment 2018–2021; 6‐month primary end point). The NTTM significantly reduced (AU$2155 per patient) patient travel cost and time and lost productivity.

Funder

National Health and Medical Research Council

Peter MacCallum Cancer Centre

Peter MacCallum Foundation

Victorian Cancer Agency

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.16292

Reference13 articles.

1. Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers

2. Teletrials: implementation of a new paradigm for clinical trials

3. Implementation of the Australasian Teletrial Model: Translating idea into action using implementation science frameworks

4. VICHealth.Victorian Patient Transport Assistance Scheme (VPTAS) 2020. Available from URL:https://www2.health.vic.gov.au/hospitals-and-health-services/rural-health/vptas-how-to-apply

5. Cents per kilometre method. Australian Government Australian Taxation Office. Last updated 21 July 2022. Available from URL:https://www.ato.gov.au/Business/Income-and-deductions-for-business/Deductions/Deductions-for-motor-vehicle-expenses/Cents-per-kilometre-method/